Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group
Lei Xu,1 Yunrong Lu,1 Ying Yang,1 Yanping Zheng,1 Fang Chen,1 Zheng Lin2 1Department of Geriatric Diseases, 2Department of Psychiatry, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People’s Republic of China Background: Bipolar disorder (BP) is a mental...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/dc87dc23ef614e7ab64aa6b3bf54b4d8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:dc87dc23ef614e7ab64aa6b3bf54b4d8 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:dc87dc23ef614e7ab64aa6b3bf54b4d82021-12-02T07:20:53ZOlanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group1178-2021https://doaj.org/article/dc87dc23ef614e7ab64aa6b3bf54b4d82015-05-01T00:00:00Zhttp://www.dovepress.com/olanzapinendashvalproate-combination-versus-olanzapine-or-valproate-mo-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Lei Xu,1 Yunrong Lu,1 Ying Yang,1 Yanping Zheng,1 Fang Chen,1 Zheng Lin2 1Department of Geriatric Diseases, 2Department of Psychiatry, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People’s Republic of China Background: Bipolar disorder (BP) is a mental illness that has a high social burden estimated by disability-adjusted life years. In the present study, we investigated the efficacy of olanzapine–valproate combination therapy versus olanzapine or valproate monotherapy in the treatment of bipolar I mania in a Chinese population group.Subjects and methods: Patients aged 19–58 years who had had an acute manic episode of BP were enrolled in the present study and randomly assigned to receive 600 mg sodium valproate daily (group A), 10 mg olanzapine daily (group B), or a combination of 600 mg olanzapine and 10 mg sodium valproate daily (group C) for 4 weeks. The primary outcome was reduction in Young Mania Rating Scale (YMRS) scores. The secondary outcome was assessed with the Clinical Global Impression – Bipolar (CGI-BP) scale. Adverse reactions, such as weight gain, sleepy, and dizziness were also evaluated. Statistical analysis was carried out on a per-protocol basis.Results: Patients in groups B and C showed significant improvement in YMRS scores compared with those in group A (P<0.01) during weeks 1–4 of treatment. Patients in group C showed significant improvement in YMRS scores compared with those in group B (P<0.01) only after 4 weeks of treatment. Furthermore, after 3–4 weeks of treatment, patients in groups B and C showed significantly greater improvement in CGI-BP scale scores compared with group A P<0.05), while Group C demonstrated significantly greater improvement in CGI-BP scale scores than group B (P<0.01). No significant difference existed in extrapyramidal reactions among these groups. Adverse reactions, including weight gain, drowsiness, dizziness, and constipation, were stronger in groups B and C than in group A (P<0.05). Conclusion: The combination therapy with olanzapine and sodium valproate had higher efficacy than monotherapy in patients with bipolar mania, which provides a crucial insight of the treatment regimen during clinical practice. Keywords: combination therapy, monotherapy, Young Mania Rating Scale score, Clinical Global Impression-Bipolar scaleXu LLu YYang YZheng YChen FLin ZDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 1265-1271 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Xu L Lu Y Yang Y Zheng Y Chen F Lin Z Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group |
| description |
Lei Xu,1 Yunrong Lu,1 Ying Yang,1 Yanping Zheng,1 Fang Chen,1 Zheng Lin2 1Department of Geriatric Diseases, 2Department of Psychiatry, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People’s Republic of China Background: Bipolar disorder (BP) is a mental illness that has a high social burden estimated by disability-adjusted life years. In the present study, we investigated the efficacy of olanzapine–valproate combination therapy versus olanzapine or valproate monotherapy in the treatment of bipolar I mania in a Chinese population group.Subjects and methods: Patients aged 19–58 years who had had an acute manic episode of BP were enrolled in the present study and randomly assigned to receive 600 mg sodium valproate daily (group A), 10 mg olanzapine daily (group B), or a combination of 600 mg olanzapine and 10 mg sodium valproate daily (group C) for 4 weeks. The primary outcome was reduction in Young Mania Rating Scale (YMRS) scores. The secondary outcome was assessed with the Clinical Global Impression – Bipolar (CGI-BP) scale. Adverse reactions, such as weight gain, sleepy, and dizziness were also evaluated. Statistical analysis was carried out on a per-protocol basis.Results: Patients in groups B and C showed significant improvement in YMRS scores compared with those in group A (P<0.01) during weeks 1–4 of treatment. Patients in group C showed significant improvement in YMRS scores compared with those in group B (P<0.01) only after 4 weeks of treatment. Furthermore, after 3–4 weeks of treatment, patients in groups B and C showed significantly greater improvement in CGI-BP scale scores compared with group A P<0.05), while Group C demonstrated significantly greater improvement in CGI-BP scale scores than group B (P<0.01). No significant difference existed in extrapyramidal reactions among these groups. Adverse reactions, including weight gain, drowsiness, dizziness, and constipation, were stronger in groups B and C than in group A (P<0.05). Conclusion: The combination therapy with olanzapine and sodium valproate had higher efficacy than monotherapy in patients with bipolar mania, which provides a crucial insight of the treatment regimen during clinical practice. Keywords: combination therapy, monotherapy, Young Mania Rating Scale score, Clinical Global Impression-Bipolar scale |
| format |
article |
| author |
Xu L Lu Y Yang Y Zheng Y Chen F Lin Z |
| author_facet |
Xu L Lu Y Yang Y Zheng Y Chen F Lin Z |
| author_sort |
Xu L |
| title |
Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group |
| title_short |
Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group |
| title_full |
Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group |
| title_fullStr |
Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group |
| title_full_unstemmed |
Olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group |
| title_sort |
olanzapine–valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar i mania: a randomized controlled study in a chinese population group |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/dc87dc23ef614e7ab64aa6b3bf54b4d8 |
| work_keys_str_mv |
AT xul olanzapinendashvalproatecombinationversusolanzapineorvalproatemonotherapyinthetreatmentofbipolarimaniaarandomizedcontrolledstudyinachinesepopulationgroup AT luy olanzapinendashvalproatecombinationversusolanzapineorvalproatemonotherapyinthetreatmentofbipolarimaniaarandomizedcontrolledstudyinachinesepopulationgroup AT yangy olanzapinendashvalproatecombinationversusolanzapineorvalproatemonotherapyinthetreatmentofbipolarimaniaarandomizedcontrolledstudyinachinesepopulationgroup AT zhengy olanzapinendashvalproatecombinationversusolanzapineorvalproatemonotherapyinthetreatmentofbipolarimaniaarandomizedcontrolledstudyinachinesepopulationgroup AT chenf olanzapinendashvalproatecombinationversusolanzapineorvalproatemonotherapyinthetreatmentofbipolarimaniaarandomizedcontrolledstudyinachinesepopulationgroup AT linz olanzapinendashvalproatecombinationversusolanzapineorvalproatemonotherapyinthetreatmentofbipolarimaniaarandomizedcontrolledstudyinachinesepopulationgroup |
| _version_ |
1718399484342304768 |